Dean Pavlick1, Alexa B Schrock1, Denise Malicki2,3, Philip J Stephens1, Dennis J Kuo4, Hyunah Ahn4, Brian Turpin5, Justin M Allen1, Mark Rosenzweig1, Kamran Badizadegan6, Jeffrey S Ross1,7, Vincent A Miller1, Victor Wong4, Siraj M Ali1. 1. Foundation Medicine, Inc., Cambridge, Massachusetts. 2. Department of Pathology, University of California San Diego School of Medicine, La Jolla, California. 3. Department of Pathology, Rady Children's Hospital San Diego, San Diego, California. 4. Division of Pediatric Hematology/Oncology, Rady Children's Hospital San Diego, San Diego, California. 5. Division of Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 6. Department of Pathology, Nemours Children's Hospital, Orlando, Florida. 7. Department of Pathology, Albany Medical Center, Albany, New York.
Abstract
BACKGROUND: NTRK fusions are known oncogenic drivers and have recently been effectively targeted by investigational agents in adults. We sought to assess the frequency of NTRK fusions in a large series of pediatric and adolescent patients with advanced cancers. PROCEDURE: Genomic profiles from 2,031 advanced cancers from patients less than 21 years old who were assayed with comprehensive genomic profiling were reviewed to identify NTRK fusions. RESULTS: Total of nine cases (0.44%) harbored NTRK fusions, including novel partners. Four of these cases were in children less than 2 years old for which infantile fibrosarcoma was considered as a diagnosis, and two harbored the canonical ETV6-NTRK3. The remaining cases carried other diagnoses, at least one that carried the diagnosis of inflammatory myofibroblastic tumor. CONCLUSIONS: NTRK fusions occur in a subset of young patients with mesenchymal or sarcoma-like tumors at a low frequency, and are eminently druggable targets via either investigational agents or approved drugs.
BACKGROUND: NTRK fusions are known oncogenic drivers and have recently been effectively targeted by investigational agents in adults. We sought to assess the frequency of NTRK fusions in a large series of pediatric and adolescent patients with advanced cancers. PROCEDURE: Genomic profiles from 2,031 advanced cancers from patients less than 21 years old who were assayed with comprehensive genomic profiling were reviewed to identify NTRK fusions. RESULTS: Total of nine cases (0.44%) harbored NTRK fusions, including novel partners. Four of these cases were in children less than 2 years old for which infantile fibrosarcoma was considered as a diagnosis, and two harbored the canonical ETV6-NTRK3. The remaining cases carried other diagnoses, at least one that carried the diagnosis of inflammatory myofibroblastic tumor. CONCLUSIONS: NTRK fusions occur in a subset of young patients with mesenchymal or sarcoma-like tumors at a low frequency, and are eminently druggable targets via either investigational agents or approved drugs.
Authors: Yu-Chien Kao; Christopher D M Fletcher; Rita Alaggio; Leonard Wexler; Lei Zhang; Yun-Shao Sung; Dicle Orhan; Wei-Chin Chang; David Swanson; Brendan C Dickson; Cristina R Antonescu Journal: Am J Surg Pathol Date: 2018-01 Impact factor: 6.394
Authors: Jason C Chang; Lei Zhang; Alexander E Drilon; Ping Chi; Rita Alaggio; Laetitia Borsu; Ryma Benayed; William D Travis; Marc Ladanyi; Cristina R Antonescu Journal: J Thorac Oncol Date: 2018-12-11 Impact factor: 15.609
Authors: Justin Taylor; Dean Pavlick; Akihide Yoshimi; Christina Marcelus; Stephen S Chung; Jaclyn F Hechtman; Ryma Benayed; Emiliano Cocco; Benjamin H Durham; Lillian Bitner; Daichi Inoue; Young Rock Chung; Kerry Mullaney; Justin M Watts; Eli L Diamond; Lee A Albacker; Tariq I Mughal; Kevin Ebata; Brian B Tuch; Nora Ku; Maurizio Scaltriti; Mikhail Roshal; Maria Arcila; Siraj Ali; David M Hyman; Jae H Park; Omar Abdel-Wahab Journal: J Clin Invest Date: 2018-08-06 Impact factor: 14.808
Authors: Cecilia Lezcano; Alexander N Shoushtari; Charlotte Ariyan; Travis J Hollmann; Klaus J Busam Journal: Am J Surg Pathol Date: 2018-08 Impact factor: 6.394
Authors: Susan Jehangir; Jujju J Kurian; Dharshini Selvarajah; Reju J Thomas; Andrew J A Holland Journal: Pediatr Surg Int Date: 2017-08-30 Impact factor: 1.827
Authors: Theodore W Laetsch; Steven G DuBois; Leo Mascarenhas; Brian Turpin; Noah Federman; Catherine M Albert; Ramamoorthy Nagasubramanian; Jessica L Davis; Erin Rudzinski; Angela M Feraco; Brian B Tuch; Kevin T Ebata; Mark Reynolds; Steven Smith; Scott Cruickshank; Michael C Cox; Alberto S Pappo; Douglas S Hawkins Journal: Lancet Oncol Date: 2018-03-29 Impact factor: 41.316